Crescent Biopharma (CBIO) Amortizatization of Intangibles (2019 - 2026)

Crescent Biopharma (CBIO) has 8 years of Amortizatization of Intangibles data on file, last reported at $97000.0 in Q1 2026.

• Amortizatization of Intangibles for Q1 2026 came in at $97000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $309000.0 (up 77.54% YoY), and the FY2025 annual result was $212000.0, down 47.35% from the prior year.
• Amortizatization of Intangibles advanced to $97000.0 in Q1 2026 per CBIO's latest filing, from $95000.0 in the prior quarter.
• Over five years, Amortizatization of Intangibles peaked at $227190.0 in Q3 2023 and troughed at $23000.0 in Q2 2025.
• A 5-year average of $166704.9 and a median of $193148.0 in 2022 frame the typical range for Amortizatization of Intangibles.
• The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles grew 10.21% in 2023, then tumbled 86.79% in 2025.
• A 5-year view of Amortizatization of Intangibles shows it stood at $213848.0 in 2022, then fell by 12.33% to $187482.0 in 2023, then retreated by 7.17% to $174048.0 in 2024, then slumped by 45.42% to $95000.0 in 2025, then gained by 2.11% to $97000.0 in 2026.
• Business Quant data shows CBIO's Amortizatization of Intangibles at $97000.0 in Q1 2026, $95000.0 in Q4 2025, and $94000.0 in Q3 2025.